Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Multiple sclerosis in Japan appears to be a milder disease compared to the UK.
Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome.
Sex-Based Differences in Multiple Sclerosis (Part I): Biology of Disease Incidence.
Telerehabilitation for persons with multiple sclerosis.
Comparison of serum vitamin D level in multiple sclerosis patients, their siblings, and healthy controls.
Clinical Neurophysiology in multiple sclerosis - From diagnostic tool to biomarker.
Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.
Personalization of multiple sclerosis treatments: using the chelation therapy approach.
More on JC viremia in natalizumab-treated patients with multiple sclerosis.
Efficacy of modafinil on fatigue and excessive daytime sleepiness associated with neurological disorders: a systematic review and meta-analysis.
Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.
The search for responsive clinical endpoints in primary progressive multiple sclerosis.
Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT.
Fatigue in multiple sclerosis: a look at the role of poor sleep.
Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4.
Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
[Semaphorin 4 in multiple sclerosis].
Protective effects of matrine on experimental autoimmune encephalomyelitis via regulation of ProNGF and NGF signaling.
A telemedicine meditation intervention for people with multiple sclerosis and their caregivers: study protocol for a randomized controlled trial.
Comparing neuromyelitis optica and multiple sclerosis severity: is there a difference?
Cost effectiveness of Sativex for spasticity in multiple sclerosis.
Self-report assessment of fatigue in multiple sclerosis: a critical evaluation.
Mesenchymal stem cells (MSC) derived from mice with experimental autoimmune encephalomyelitis (EAE) suppress EAE and have similar biological properties with MSC from healthy donors.
Intramuscular IFNß-1a in multiple sclerosis: 'no proof of effectiveness' or 'proof of no effectiveness'?
Pages
« first
‹ previous
…
650
651
652
653
654
655
656
657
658
…
next ›
last »